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ABSTRACT
The surviving fraction of cells following irradiation is affected by the temporal
pattern of dose delivery. Modern technology for external beam radiation therapy
allows complex manipulation of both the spatial and temporal pattern of dose
delivery during a single treatment fraction. The aim of this thesis was to
investigate the influence of temporal dose effects in external beam radiotherapy,
and predict the potential for biological optimisation when the pattern of dose
delivery is manipulated to achieve maximum effect in the target.
A radiobiological model, based on the linear quadratic formalism and including
the pattern of dose delivery of individual voxels, was used to calculate the cell
surviving fraction across the target volume. Dose patterns were manipulated to
optimise cell kill and predict the potential for biological optimisation. Prostate
external beam treatments were chosen as the clinical site to investigate due to the
sensitivity of prostate carcinoma to temporal dose effects.
For clinical treatment plans, the biological effect due to the original dose
prescription was found to vary across the target volume when temporal dose
effects are incorporated. The percentage difference in cell surviving fraction
between the prescribed treatment and that with temporal effects included was
found to be on average 27% for 3DCRT and 87.6% for IMRT treatments. Over
the whole target volume this corresponded to a decrease in treatment effectiveness
[assessed using equivalent uniform dose (EUD)] of 1.3% and 3% for 3DCRT and
IMRT respectively. The distribution of biological effect was visualised on the
original treatment plans. This gave insight into the areas of the prostate which are
most likely to be affected by the temporal dose pattern. Generally, the middle of
the prostate was found to exhibit a biological ‘under dosing’ due to this region
receiving sub-optimal dose arrangements.
For the theoretical scenario of optimising the temporal dose pattern to every voxel
in the target volume the impact on treatment effectiveness was found to be modest
ii

– on average a 0.8% increase in EUD for a 2 Gy per fraction IMRT treatment
plan. Larger effects were observed for larger dose per fraction treatments. A 1.4%
increase in EUD was calculated for an 8 Gy per fraction treatment.
The final stages of this thesis investigated if simply altering the order of treatment
beam delivery could provide biological optimisation over the whole target area
due to the change in temporal dose arrangements. Generally, the treatment beam
order that delivered the fastest treatment was found to be biologically optimal due
to the minimisation of sublethal damage repair.
This investigation has shown that the temporal pattern of dose delivery is an
important component when determining the biological effect of external beam
treatments. It is recommended that temporal dose effects can and should be
considered when planning modulated and/or hypofractionated treatments where
the treatment time is of the same order as the half-time for repair of sublethal
damage of the tissue. Where appropriate, it would be advantageous to irradiate
target volumes as rapidly as possible.
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1 INTRODUCTION
1.1

Background

In 2012, an estimated 121 500 new cases of cancer were diagnosed in Australia
(AIHW, 2012). According to the Australian Institute of Health and Welfare
(AIHW), one in two men and one in three women will be diagnosed with cancer
before the age of 85. The number of cancer cases is generally likely to continue to
rise, largely due to population growth, an ageing population and improved early
detection methods for some cancers. Prostate cancer is the most common cancer
in males, with 19 403 new cases diagnosed in 2007 (AIHW, 2010).
Radiotherapy is one of the two most effective treatments for cancer and has
replaced surgery for the long-term control of many tumours of the head and neck,
cervix, bladder and prostate. Radiotherapy has the ability to provide local control
by eradicating the tumour and surrounding microscopic disease. Currently, around
50% of cancer patients will receive radiotherapy as part of the management of
their disease, with most of these treatments being for curative intent (AIHW,
2010).
The whole objective of curative radiotherapy is to deliver a lethal dose of
radiation to the tumour while incurring minimal damage to the surrounding
healthy tissues. There are many factors affecting the outcome of a radiotherapy
treatment. The spatial conformality of the high dose region to the tumour volume
has a large effect but there are also many radiobiological factors that can influence
the treatment: specifically the 5Rs of radiobiology. These are; the differential
repair of tumour and normal cells between treatment fractions, the redistribution
of cells into more or less radiosensitive phases of the cell cycle, the repopulation
of tumour cells between fractions, the re-oxygenation of tumour cells during
treatment and the intrinsic radiosensitivity of the cells (Joiner & van der Kogel,
2009). It is therefore essential to be able to accurately predict the dose distribution
and biological response of tumours and normal tissues in the treatment planning
stage of radiotherapy. Traditionally, these radiobiological factors are taken into
1

account by optimising the daily fractionation schedule, but recent investigations
have shown the duration of each individual fraction (Benedict et al., 1995 &
1997; Mu et al., 2003; Wang 2003), and also the sequence of radiation delivery
during individual fractions (Lin & Wu, 2005; Murphy et al., 2007; Altman et al.,
2006 & 2009) to have a clinically significant impact on treatment outcome.
1.1.1 External Beam Radiation Therapy
External beam radiation therapy (EBRT) is the most common form of radiation
therapy. Radiation beams produced externally are projected on to the patient.
Megavoltage x-rays, created by a linear accelerator (linac), are used to treat deepseated tumours. Superficial lesions can be treated using kilovoltage x-rays,
produced with conventional x-ray tubes, or with high-energy electron beams
produced by linacs.
The first step in the EBRT process is to obtain the patient’s anatomical
information. This is achieved with either computed tomography (CT) or with a
radiotherapy simulator. The images are then transferred to the treatment planning
system (TPS) where the oncologist outlines the tumour volume in the patient. The
outline of the gross tumour volume (GTV) is grown by a pre-determined margin
to obtain a planning target volume (PTV), which encompasses patient setup errors
- as defined by the ICRU Report 62 (1999). The oncologist prescribes a dose of
radiation to be uniformly delivered to the PTV and a dose limit to surrounding
critical structures. Using the treatment planning system, the optimum treatment
configuration can then be determined. The number of beams and their angles,
field sizes, wedges, multi-leaf collimation, blocking, beam weights, monitor units
can all be adjusted in order to achieve the optimum dose distribution.
The irradiated volume is divided into a 3D dose grid, or voxels (volume
elements). The dose deposited to each voxel for each beam is calculated by the
TPS using complicated algorithms and the patient’s anatomical information. The
dose distributions are visualised in 2-D (axial, coronal and sagittal planes) using
isodose curves. The 2-D dose distribution in conjunction with dose volume
histograms (DVH) are used to evaluate the treatment plan. The final product of
2

treatment planning is the treatment sheet, which includes the prescription and
provides a set of instructions for the radiation therapist, enabling the treatment
beams to be delivered as planned to achieve the desired dose distribution.
The process described above is known as three-dimensional conformal
radiotherapy (3DCRT). The multi-leaf collimators (MLCs) in the head of the linac
are utilised to shape the radiation field to give a “beams eye view” of the target at
that particular gantry angle of the linac. The radiation beams delivered are
homogeneous in intensity across the beam. Unfortunately, conformality of dose to
complex target volumes cannot be achieved via simple “beams eye view”
planning.
This lead to the introduction of intensity modulated radiation therapy (IMRT).
Here, the MLCs of the linac are swept across the radiation field to produce nonuniform radiation intensities across the beam. The resultant dose distribution can
contain large doses and high dose gradients. This allows the radiation to be
conformed to complex target volumes, for example concave targets such as a
tumour surrounding the spinal cord. With IMRT a high and spatially uniform dose
of radiation can be delivered to the tumour, whilst the high dose gradients allow
for sparing of the spinal cord.
IMRT delivers dose either statically or dynamically. In each case radiation is
delivered through a sequence of windows formed by the leaves. In the static, or
step-and-shoot, method of delivery the dose is only delivered when the MLC
leaves are stationary and there is no dose delivered as the leaves move to the next
position. In dynamic delivery, the corresponding leaf pairs sweep simultaneously
and uni-directionally, each with a different velocity as a function of time. The
time period that the aperture between leaves remains open allows for the intensity
modulation of the beam.
For IMRT planning a technique known as inverse planning is generally used. In
this method the beam shapes and profiles are automatically computed by the TPS
from the desired dose distribution. The planner specifies beam directions (linac
3

gantry angles), target dose goals, and dose constraints or goals for sensitive
structures, and then an automated optimisation algorithm calculates intensity
patterns that create a dose distribution to best meet the prescription.
Although IMRT has proven to be beneficial clinically for numerous tumour sites,
there are some radiobiological issues that are not fully understood. IMRT has
been associated with prolonged fraction times (from 5 to 30 minutes) depending
on the site and complexity of treatment. Prolonged fraction times can lead to
reduced cell kill due to increased repair of sublethal damage within the treatment
fraction. Furthermore, recent investigations have shown the radiobiological
outcome of a radiotherapy treatment is influenced not only by prolonged fraction
times but also by the pattern of dose deposition. Thus, there may be the potential
to optimise patient treatment by manipulating the temporal patterns of dose
deposition.
1.2

Thesis Outline

The aim of this thesis will be to predict, via radiobiological modelling, the effect
of inhomogeneous temporal dose distributions on treatment outcome. Chapter 2
will provide a review of radiobiological models and previous in vitro and
modelling studies examining intra-fraction repair and the effects of the temporal
pattern of dose delivery. Chapter 3 will outline in detail the radiobiological model
used in calculations. Chapter 4 presents an examination of the influence of
radiobiological parameters on the model. Chapters 5 and 6 will be devoted to
optimising radiotherapy treatments over a single voxel and over the whole PTV,
based on predictions of the model. The project will concentrate on optimisation of
external beam treatments for prostate cancer, although the radiobiological model
can be applied to any site.

1.3

Aims and Objectives
1. To predict the influence of input parameters on the model

Radiobiological parameters generally have large confidence intervals. The effect
of radiobiological parameters; the alpha beta ratio and the half-time for repair of
4

sublethal damage, as well as treatment parameters; fraction time and dose, will be
examined in chapter 4.
2. To predict the influence of temporal dose history on cell survival
The second aim of the project is to incorporate individual dose histories for each
voxel into radiobiological modelling to predict the variation in cell kill across the
entire PTV. Chapter 2 will provide a review of current radiobiological models to
predict cell kill.
3. To optimise cell kill across the PTV
The aim of the final stages of this project is to attempt to optimise treatment
outcome by manipulating the treatment times and the sequence of beam delivery.
Previous studies have looked at optimisation due to the sequence of dose delivery
in a single voxel only. Chapter 6 will use biological evaluation tools, such as
equivalent uniform dose (EUD), to optimise treatment over the entire PTV.

5

2 MODELS FOR INTRA-FRACTION REPAIR EFFECTS

Radiobiological modelling can be a useful tool in predicting the biologic outcome
of radiotherapy treatments on tumour and normal tissue cells. Mathematical
models bridge the gap between biology and physics – reducing complex
biological mechanisms to relatively simple and robust formulas. The models are
derived from either a mechanistic approach or empirical observations. Empirical
models have been fitted to both in vitro and in vivo experimental data, but have no
real account for the underlying principles. Mechanistic models aim to incorporate
some of the underlying radiobiological response mechanisms. A complete
description requiring extensive detail is beyond the scope of this thesis. An
excellent summary can be found in Hall (1994).
2.1

Radiation Induced Cell Kill

The effect of radiation interaction with cells causing death is extremely
complicated and likely involves multiple complementary and competing
processes. The description given here is based on experimental observations of the
last few decades and which is generally consistent with clinical observations of
the effect of time, dose and fractionation on cellular response.
When ionising radiation strikes a cell, lesions to the cell’s DNA strand are
produced. Double and single strand breaks can be created either directly by the
ionising radiation or indirectly as a result of free radicals produced by the
radiation interactions in surrounding molecules. For example, the interaction of
radiation with water produces extremely reactive radicals; H2O+ (water ion) and
OH- (hydroxyl radical), able to produce DNA strand breaks.
Single strand breaks (SSB) of DNA are of little biological consequence as far as
cell kill is concerned because they are easily repaired. Cell kill occurs when there
is a break in the two DNA strands opposite each other, or separated by only a few
base pairs, ie a double strand break (DSB). DSBs are the most important lesions
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with respect to cell death; a DSB can lead to direct cell kill, can interact with
another DSB to form cell kill or mutations, or can be repaired. Radiation damage
to cells is consequently divided into three categories – lethal damage, which is
irreparable and leads to cell death; sublethal damage, which can be repaired within
hours unless it interacts with additional sublethal damage to form lethal damage;
and potentially lethal damage, which is the component of radiation damage that
can be modified by post irradiation environmental conditions.
2.2

Factors Influencing Cellular Response

There are many factors that influence the cellular response of irradiated tissues
during a course of radiotherapy. The main factors are; repair of sublethal damage,
cell-cycle redistribution, cellular repopulation, tumour reoxygenation and intrinsic
radiosensitivity. These factors are mainly associated with dose and time, and are
commonly known as the 5 Rs of radiobiology (Metcalfe, Hoban & Kron 2007).
2.2.1 Dose
2.2.1.1 Cell Survival Curve
A cell that is able to proliferate indefinitely and form a large colony from a single
cell is said to be clonogenic. In radiotherapy, loss of the cell’s clonogenicity is
considered to be cell death. Cell survival is therefore determined by irradiating
tumour cells and measuring the loss of cell proliferation. Cell survival curves
describe the relationship between the radiation dose delivered and the proportion
of the cells that survive. This is represented graphically by plotting the surviving
fraction on a logarithmic scale against the dose on a linear scale (as in figure 2-1).
The log of fractional survival (S) may be parameterised as the sum of the linear
and quadratic curves, which is consistent with the mechanism of cell death
discussed in section 2.1 above. For total dose, D:

−ln(S) = αD + βD2 !

( 2.1 )

Here the linear term has coefficient α (Gy-1), and describes the initial linear
section of the curve. This section of the curve represents the cell’s intrinsic

€
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radiosensitivity and is related to non-repairable cell kill via single radiation
events. The curved section is described using a quadratic term with coefficient β
(Gy-2). This section represents cell damage from multiple radiation hits, which
may be repairable with time. The ratio of α to β is therefore an indicator of a cell’s
sensitivity to alterations in fractionation scheme or dose-rate. The amount of
curvature of the cell survival curve depends on β, and represents a repairable type
of damage with time. Cells with large beta components are therefore sensitive to
dose per fraction and dose rate variations. The values of α and β vary widely for
various tissue types. However, α/β values of 10 Gy and 3 Gy are commonly used
for tumour and normal tissue respectively.

Figure 2-1 Cell survival curve for typical tumour (α/β = 10 Gy) and late responding normal
tissue (α/β = 3 Gy).

The cell survival curve forms the rationale for fractionation in radiotherapy
treatments. Figure 2-1 shows at low doses of radiation the survival fraction for
normal tissues is greater than for tumour cells. Fractionation takes advantage of
this effect by delivering small doses of radiation over multiple treatment fractions.
Figure 2-2 demonstrates how fractionation improves the therapeutic ratio by
widening the gap between normal tissue and tumour survival fraction,
consequently increasing tumour control and sparing normal tissues.
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Figure 2-2 The rationale for fractionated radiotherapy. The surviving fraction of cells is
greater for the late reacting normal tissue compared to the tumour for the same dose
fractionation scheme.

2.2.1.2 Radiosensitivity
The term radiosensitivity can have a number of meanings. It is generally used to
refer to cells from different types of tissues exhibiting different levels of steepness
in their cell survival curves (Steel et al. 1989). This effect is taken into account by
the unique alpha and beta values for all tissue types. Tumours are often referred to
as early responding tissues because they respond to radiation after a short amount
of time. Normal tissues are mostly late responding, with the exception of some
normal tissues such as skin and mucosa, as they do not show effects for a longer
time.
A cell’s response to radiation has also been shown to depend on the amount of
dose delivered. Low dose hyper-radiosensitivity (HRS) has been observed in
tumour cells and some normal tissue cells at doses per fraction of around 0.5 Gy
or less. The biological effect has been shown to be greater than predicted by the
standard linear quadratic model. Conversely, a resistance to cell killing has been
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observed for doses between 0.5 and 1 Gy. This is known as induced
radioresistance (IRR) (Joiner et al. 2001).
Radiosensitivity also depends on a cell’s position in its mitotic cycle. The late G2
and M phases are the most radiosensitive phases, whereas the late S phase is the
most radioresistant.
2.2.2 Time
2.2.2.1 Proliferation and repopulation
Each fraction during a radiotherapy treatment reduces the number of clonogenic
cells in a tumour. Clonogenic cells that survive radiation can repopulate the
tumour by proliferation and thereby reduce the efficacy of the treatment.
Treatment with radiation could also trigger surviving cells in a tumour to divide
faster than before. This is known as accelerated repopulation. Head and neck
tumours have been observed to start to grow more rapidly between two to four
weeks after the start of radiotherapy. This time is referred to as the time for
kickoff, Tk. Radiotherapy treatments of rapidly proliferating tumours should
therefore be completed as soon as is practical and techniques such as
hyperfractionation and accelerated treatments should be considered. An indication
of the proliferative power of a tumour can be gained from the potential doubling
time Tpot. Tpot is the time required to double the cell population assuming no cell
loss has occurred. Head and neck squamous cell carcinomas typically have
doubling times of 3 to 4 days, while prostate carcinomas are slow proliferating
tumours and typically have a Tpot of 60 days (Metcalfe, Hoban & Kron 2007). An
extension of the LQ equation taking into account Tk, Tpot and overall treatment
time, T, is required for rapidly proliferating tumours. Here n is the number of
fractions, and d is the dose per fraction:

⎛
⎞
ln2
S = exp⎜⎜ −nd(α + βd) +
(T − Tk )⎟⎟
Tpot
⎝
⎠

€
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( 2.2 )

2.2.2.2 Repair of sublethal damage
During irradiation, single strand DNA breaks are up to 50 times more prevalent
than double strand breaks. SSBs and base damage to DNA also occur naturally –
it is estimated up to 100,000 damages occur in each cell of the body every day
(Joiner & van der Kogel, 2009). SSBs are therefore very easily repaired by the
body. DSBs also undergo repair mechanisms; only a fraction of the DSBs
produced will lead to lethality. Figure 2-3 summarises the processes leading to
either repair or misrepair of DSBs. Figure 2-3A shows two chromosomes each
with one DSB. After being produced, most DSBs undergo restitution (Figure 22B), where the two free ends are rejoined to the chromosome. Figure 2-3C shows
the formation of a dicentric chromosome aberration and an acentric fragment.
This formation leads to cell lethality as it destroys the clonogenic viability of the
cell. The two DSBs can also lead to translocation as shown in Figure 2-3D.
Translocation involves large-scale cellular rearrangements, but generally does not
alter cell survival and is therefore considered to be non-lethal binary misrepair.

Figure 2-3 Shown above are examples of binary misrepair: (A) two chromosomes each with a
DSB, (B) viable restitution of each chromosome, (C) lethal binary misrepair (dicentric and
acentric formation), and (D) viable binary misrepair (translocation) (Sachs et al. 1997).

Evidence for sublethal damage repair includes split dose experiments (Elkind &
Sutton, 1960) which show that when dose is delivered in two fractions – separated
by a time interval of several hours, the fraction of surviving cells is greater than if
the dose is given as a single exposure. The typical timing of split dose recovery is
11

shown in figure 2-4. Considerable recovery occurs between 15 minutes to an hour
after irradiation. The surviving fraction increases until a plateau is reached at
about 2 hours (figure 2-4B). Recovery is complete by 6 hours. Consequently, it is
recommended to leave at least 6 hours between fractions of radiotherapy to allow
for the repair of normal tissues between fractions. The dotted line in figure 2-4B
shows a dip in the cell survival between 2 and 8 hours. This is caused by reassortment in rapidly dividing cell lines – the survivors of the first dose of
radiation are predominantly in a resistant phase of the cell cycle. When the
interval between doses is about 6 hours the resistant cells have moved to the G2M phase, making them more sensitive to radiation. If the time interval between
doses increases to beyond the cell cycle time (10 to 12 hours), proliferation and
repopulation occurs increasing cell survival.

Figure 2-4 Diagram summarising the repair of sublethal damage through split dose
experiments. A) When dose is delivered in two equal fractions separated by a time interval,
there is an increase in cell survival. B) Surviving fraction of cells from split dose experiments
as a function of the time between the doses (Hall, 1994).

The repair half-time is a parameter used to describe the rate of repair of sublethal
damage in various tissues. This parameter is determined by estimating values that
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best describe cell survival curves of irradiated cell lines. It has a large uncertainty
due to the varying environmental conditions of the cells. Brenner and Hall (1991)
report the most probable value for the repair half-time for human tumours is 20
min. Thames, Withers, and Peters (1984) report that the half time for repair of
late responding normal tissues is significantly greater than one hour.

2.2.2.3 Fractionation
The dose-time-fractionation scheme is one area of radiotherapy that can be
optimised to improve therapeutic gain, and is usually a balancing act between
achieving tumour control and avoiding normal tissue toxicity. The main factors
influencing a fractionation scheme are dose per fraction, number of fractions, time
interval between subsequent fractions, and the overall time and dose.
Fractionation schemes are designed to exploit the difference in the repair capacity
of sublethal damage between early responding (tumour) and late-responding
(normal) tissue. The time in between fractions of radiation dose allows normal
tissues to repair and repopulate, and increases the damage to tumour cells through
the reoxygenation of hypoxic cells and the redistribution of cells to more sensitive
stages of the cell cycle. Conventional fractionation uses doses of 2 Gy per fraction
with five fractions per week (Monday to Friday) and total doses generally ranging
from 40 to 70 Gy. Hyperfractionation is the term used to describe radiotherapy
with doses per fraction less than 2.0 Gy, but with the number of fractions
increased to two per day. Hyperfractionation and accelerated treatment schemes
are used in tumours exhibiting significant proliferation and repopulation as
discussed previously in section 2.2.2.1.
Hypofractionation is the use of a dose per fraction greater than 2.0 Gy, but with
the total number of fractions reduced. Hypofractionation is widely used in
palliative radiotherapy where normal tissue complication is of little concern due to
the life expectancy of the patient. Hypofractionation is also commonly used for
stereotactic radiotherapy of small tumours. Here steep dose gradients can be
achieved reducing the volume of normal tissue at risk of radiation damage.
Hypofractionation of prostate carcinoma is becoming popular due to its reportedly
13

low alpha beta ratio (1.5 Gy; Brenner & Hall 1999, Fowler et al. 2001). The low
alpha beta ratio of prostate cancer implies a higher radiosensitivity to fraction
size. Hypofractionation of prostate cancer treatment will only lead to an increase
in therapeutic gain if the alpha beta ratio of prostate is lower than the adjacent
surrounding normal tissues such as the rectum and bladder. There are numerous
clinical trials on the hypofractionation of prostate cancer that show improved or
equivalent tumour control whilst maintaining acceptable normal tissue
complications. The reported dose per fraction schemes range from 2.5 Gy/fraction
in 28 fractions (Djemil et al. 2003) up to 7 Gy/fraction (Tang et al. 2008)
delivered in 5 fractions. Shorter hypofractionation schedules, consisting of only 45 (up to 10 Gy/fraction) are now also beginning to be explored, although not
always within clinical trials.

2.2.2.4 Overall treatment time
For most tumour types the biological effect of a specific dose-fractionation will
decrease as overall treatment time increases. A study by Yang and Xing (2005)
investigated different dose-time fractionations for fast and slow proliferating
tumours. The results indicated for fast proliferating tumours the greatest
biological effect occurs when the overall treatment time is similar to Tk. For
slowly proliferating tumours, no biological advantage was found for short overall
treatment times.
Unplanned gaps in treatment are a problem frequently encountered in
radiotherapy. A modelling study by Hendry et al. (1996) suggests for head and
neck cancer there is approximately a 1.6% decrease in local tumour control
probability per day of treatment prolongation. There are many non-treatment days
for conventional treatments, for example, weekends, public holidays, and the
service or breakdown of treatment equipment. Interruptions can also be caused by
patient factors such as illness or severe reactions to the radiation. Hendry et al.
(1996) recommend avoiding gaps wherever possible, or actively modifying the
treatment after a gap by; A) treating on weekends or using two fractions per day
to maintain the overall time and fraction size. B) Increasing the size of the dose
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per fraction to maintain the overall treatment time. C) Accept the protraction
caused by the missed treatment days and add the missed fractions to the end of the
treatment. In all cases the consequent change in biological effect for the tumour
and normal tissues should be considered.

2.3

Linear Quadratic Formalism

The LQ model describes cell killing in terms of the following mechanisms
described in section 2.2.2.2. Overall the yield (Y) of lethal lesions and the
corresponding cell surviving fraction S are:
Y ∝ αD + GβD2 !

( 2.3 )

then assuming the lethal lesions are Poisson distributed from cell to cell, the
€
surviving fraction will be:
S = exp(−Y )

( 2.4 )

S = exp( −αD − GβD2 ) !

( 2.5 )

and thus
€

S is the cell survival probability, G is the Lea-Catcheside dose-protraction factor
€
(Lea, 1946), D is the dose, and alpha and beta are constants characteristic of a
given tissue or tumour type, as described previously in section 2.2.1.1. This
equation mathematically describes the curve in figure 2-1.
The Lea-Catcheside dose-protraction factor is given by:

G=

2
D2

∫

T
0

t

R(t)dt ∫ 0 e − λ (t −t' )R(t')dt'

( 2.6 )

Here lambda is the tissue specific repair parameter, related to the half-time for
repair of SLD, T1/2, via:

€

λ=

ln(2)
T1
2
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( 2.7 )

R(t) is the time varying dose rate and T is the overall treatment time. t’ is the time
at which a primary lesion occurs and is subject to first-order repair with repair
time constant λ. If the primary lesion is not lethal, i.e. a double strand break, it
may interact with a second lesion produced at time t, to create a two-track lethal
lesion. G therefore modifies the quadratic term of the LQ equation to account for
the sublethal damage repair of protracting the dose delivery in any way. If the
delivery of D is instantaneous then G = 1, for any other dose delivery pattern G <
1.
In Wang et al.’s 2003 paper, the general form of G is modelled using an
analytical solution:
i−1
⎫⎪
2 N ⎧⎪
λt j
λt j −1
− λ (t i −t i −1 )
− λt i −1
− λt i
G = 2 2 ∑ Ii ⎨ Ii [ λ(t i − t i−1 ) − (1 − e
)] + ∑ I j (e − e )(e
− e ) ⎬
⎪⎭
λ D i=1 ⎪⎩
j =1

( 2.8 )

€

Here, Ii is the dose rate of the ith segment, to the particular voxel, and, where i =
1 to N. N is the total number of time segments. λ is the tissue specific repair
parameter (equation 2.7).
For fractionated radiotherapy:

[

]

S = exp( −αd − G(t) βd 2 )

n

( 2.9 )

where n is the number of fractions and d is the dose per fraction. The LQ model

€
comes in various
degrees of complexity depending on the number of “Rs” of
radiobiology that are incorporated. For tumours that are capable of rapid
proliferation, fractionation of treatments allows surviving clonogenic cells of the
tumour time to repair and repopulate (see equation 2.2).
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2.3.1 Limitations of the LQ Model
The LQ model is widely used in radiotherapy to mathematically describe the
effect of ionising radiation on tumour and normal tissues. This model was initially
derived to fit experimental observations of the effects of dose and fractionation,
but its underlying mechanistic basis has also been demonstrated (Sachs &
Brenner, 1998). The appropriateness of using the LQ model for large dose per
fraction schedules such as in radiosurgery and brachytherapy has been questioned
(Joiner & Van der Kogel 2009; Kirkpatrick et al. 2008). The authors argue the LQ
model is only supported by data in the dose region of 1 to 5 Gy per fraction.
Brenner, (2008) demonstrates the LQ model based on both experimental and
theoretical considerations is a plausible model in the dose range of 2 to 10 Gy.
Above 10 Gy, the model would be expected to become progressively less
accurate, but still acceptable.
Another limitation of LQ formalism is the lack of appropriate parameter
estimates. Available estimates often have large 95% confidence intervals,
resulting in a large variation in model predictions.
A further issue regarding the LQ model is the move towards the increasing use of
combined modality therapy (e.g. chemotherapy) in many tumour types. Some
cytotoxic and molecular targeted drugs have been shown to modulate the dosetime fractionation response of the tissues (Bentzen et al. 2007) – rendering any
LQ calculations for the radiotherapy treatment schedule futile.

2.4

Biologically Effective Dose

A common method of quantifying the effect of a treatment scheme is to calculate
the biologically effective dose (BED). The BED formula employed for clinical
applications in external beam fractionated radiotherapy is:

BED = −

⎛ G(t)d ⎞
ln S
= nd⎜1+
⎟
α
α / β ⎠
⎝

€
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( 2.10 )

and was first introduced by Barendsen (1982) as Extrapolated Response Dose
(ERD). BED takes into account the radiobiological parameters of tumour and
normal tissues (alpha, beta) as well variables previously defined in section 2.3.
For any normal or tumorous tissue, an increased BED indicates and increased
biological effect, that is, a reduced surviving fraction, S. The dose protraction
factor, G, can be incorporated into the BED calculations if it is assumed the repair
halftime is much smaller than the time between successive fractions.

2.5

Equivalent Uniform Dose

The equivalent uniform dose (EUD) concept was first introduced by Niemierko
(1997) to provide a means of comparing treatment plans with inhomogeneous
dose distributions. The concept of EUD assumes that any two dose distributions
are equivalent if they cause the same radiobiological effect. EUD is therefore
defined as the equivalent dose that, if distributed uniformly across the tumour
volume, will lead to the same level of cell kill as a non-uniform dose distribution.
EUD calculations can be extended to include non-uniform density of clonogens,
dose per fraction effects, repopulation of clonogens and inhomogeneity of patient
populations (Niemierko, 1997). For the generalised LQ cell survival model the
EUD formula can be written as:

EUD =

−log(S)
(α + βd)

( 2.11 )

where alpha and beta are the LQ parameters for the tissue type and d is the dose
€ the EUD is defined relative to, (ie d = 2 Gy) (Wang and Li,
per fraction in which
2003).To account for dose inhomogeneity, the surviving fraction, S, is calculated
based on dose-volume histogram (DVH) data.

S = ∑ v k S(Dk )

( 2.12 )

k

Where vk is the fractional volume of the dose bin Dk in the DVH, and S(Dk) is
calculated using the €
LQ model (equation 2.9 above).
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2.6

Consideration of Intra-Fraction Repair in Radiotherapy

In radiation therapy there are multiple timescales to consider; the daily
fractionation schedule, the duration of each fraction and the intra-fraction
sequence for delivering individual radiation fields (Murphy et al., 2007). Complex
treatments such as intensity modulated radiation therapy (IMRT), volumetric
modulated arc therapy (VMAT) and stereotactic radiotherapy are becoming
increasingly popular in radiotherapy. Both stereotactic and IMRT treatments are
associated with prolonged fraction times. IMRT and VMAT use highly spatially
and temporally modulated fields to achieve dose conformality to the target
volume while avoiding normal tissues. This improves the spatial distribution of
dose, but creates non-uniform dose rates across the treatment volume.

2.6.1 Intra-Fraction Treatment Time
The duration of individual fractions influences cell survival rate. Both in vitro
radiobiological experiments (Benedict et al., 1995 & 1997; Mu et al., 2003;
Bewes et al., 2008) and calculations based on the linear quadratic model (Wang et
al., 2003) have shown greater cell survival for long treatment fractions compared
to short treatment fractions. Long fraction times are associated with complicated
techniques such as IMRT and stereotactic radiotherapy. Conformal radiotherapy
generally takes 2 to 5 minutes between the start and finish of dose delivery,
whereas an IMRT treatment can take up to 30 minutes depending on the site and
complexity of the treatment.

Benedict et al. (1995 &1997) compare the biological effect for continuous versus
intermittent radiation treatments, specifically, Gamma Knife (Elekta Pty Ltd,
Australasia) versus linac based stereotactic radiosurgery procedures. Cell lines
were irradiated to 12 Gy for a continuous 5-minute exposure and an intermittent
exposure lasting up to 112 minutes. The results show a 40% increase in cell
survival in malignant glioma cells when the treatment time for 12Gy was
increased from 5 minutes of continuous radiation to 60 minutes of intermittent
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irradiation. They suggest a dose correction factor of 0.02 to 0.03 Gy/min be
applied for delivery times exceeding 16 minutes.
Wang et al. (2003) investigated the protraction effect with respect to IMRT for
prostate cancer. Using an alpha beta ratio of 3.1 Gy and repair half-life of 16
minutes they show when fraction delivery time is increased from 2-5 minutes for
conventional radiotherapy to 30 minutes for an IMRT treatment the TCP was
found to decrease from 95% to 73%, which may be clinically significant. Fowler
et al. (2004) also report clinically significant loss in biological effect for
protracted delivery times associated with IMRT. Two values for repair half-time
were used in calculations rather than a single value since it is generally accepted
that a continuous distribution of repair rates exist. This gives the best compromise
between accuracy and ease of calculation. Both studies indicate that if fraction
times are greater than 15 minutes the prescription dose should be increased (either
dose/fraction or number of fractions) to compensate for the reduction in cell
killing due to increased sublethal damage repair.

2.6.2 Intra-Fraction Treatment Sequence
There is also mounting evidence to suggest the intra-fraction sequence of dose
delivery has an effect on the amount of cell kill (Lin & Wu, 2005; Murphy et al.,
2007; Altman et al., 2006 & 2009).
Lin and Wu (2005) first demonstrated that cell survival varies with the sequence
of applied doses. They show that cell kill is greater when a fraction of 2 Gy is
delivered in a sequence of 2 small increments followed by 1 large increment
opposed to when a large dose increment is delivered followed by 2 small
increments.
Murphy et al. (2007) have recently investigated the spatio-temporal variation of
dose delivery in Cyberknife (Accuray, Sunnyvale, California) treatments. One
hundred or more beams of sizes smaller than the size of the tumour are delivered
sequentially, causing parts of the tumour to be irradiated at different times and in
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different dose increments. Figure 2-5 shows the incremental dose buildup of two
different voxels within a lung tumour irradiated by the Cyberknife, and illustrates
the problematic issues with dose delivery sequence. Voxel B is shown to
accumulate dose faster than voxel A, which receives a small increment of dose
followed by a 20-minute pause. Voxel B’s effectiveness is reduced to 98% of the
prescription dose, while voxel A’s effectiveness is reduced to 89% of the
prescribed dose. The authors argue the time-course in which dose is deposited is a
significant factor in determining cell response.

Figure 2-5 The buildup of dose over time for 2 voxels in a lung tumour Cyberknife treatment
(Murphy et al. 2007).

Altman et al. (2006) have modelled temporal effects using the linear quadratic
model. A simplified model of an IMRT treatment was used. This consisted of
analysing results in a single voxel only, where the dose pattern indicative of a
typical IMRT treatment was created by alternating periods of ‘beam-on’ and
‘beam-off’ times. Within each beam-on period, the dose rate is assumed to be
constant. The analytic solution to the protraction factor, G (see equation 2.8),
initially described by Wang et al. (2003), was used in the calculation of cell
survival.
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The results obtained indicate that the temporal pattern of dose deposition can be
arranged to maximise or minimise cell kill. Maximum cell kill occurs when the
highest doses are applied to the middle of the treatment, and the lowest doses at
the beginning and end (‘pyramid’ shape). Minimisation of cell kill is achieved by
concentrating the lowest doses in the middle of the treatment period (‘V’ shape).
These results are in agreement to effects observed by Murphy and Lin and Wu.
This work has considered temporal dose effects in a single voxel only, rather than
the distribution of these effects across the entire target volume. Results for cell
surviving fraction are expected to vary across the target volume due to the varying
dose histories associated with modulated treatments.

Figure 2-6 The arrangement of 9 radiation beams delivering a total of 2Gy to a single voxel
yielding: (a) maximum cell kill (b) minimum cell kill (Altman et al. 2006).

Altman et al. (2009) validated their findings with in vitro experiments on three
cell lines: WiDr a clonoic adenocarcinoma line (low α/β), PC-3 a prostate
carcinoma line (low α/β) and SQ-20B a head-and-neck squamous cell carcinoma
(high α/β). Each cell line was irradiated in a solid water phantom with 6MV
photons at 600 MU/min and received a total dose of 900cGy delivered over 20
minutes. The dose was delivered in six fields arranged in either a triangle or Vshaped pattern. Results for the V-shaped pattern show an increased cell survival
compared with the use of a triangle pattern: 21.2% for WiDr, 18.6% for PC-3and
4.7% for SQ-20B. These results validate the modelling studies predicting that the
pattern in which dose is applied can influence cell survival despite the total dose
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delivered and time for delivery remaining constant. The greatest differences were
seen in tissues with a large β (i.e. low α/β) and for high doses per fraction and
long fraction times.
2.6.3 Site Sensitivity
Prostate treatments were chosen as the clinical site to investigate intra-fraction
temporal effects in external beam radiotherapy. The prostate was chosen as it is
slowly proliferating and has a reported low alpha beta ratio, and short repair halftime. This indicates prostate carcinoma will be sensitive to intra-fraction temporal
effects due to it’s large capacity for repair (large β component) and the relatively
short repair half-time of sublethal damage.

2.6.3.1 Alpha and Beta Values of Prostate Carcinoma
The α and β values from the linear-quadratic model (see section 2.2.1.1) indicate
the sensitivity of a specific cell type to dose and changes in dose-fractionation.
The ratio of alpha and beta values (α/β) is used as a scaling factor to convert
physical doses to a relative measure of biological effect – the biologically
effective dose (BED). α/β of the prostate is a highly debated topic in radiotherapy.
The α/β value for a tumour is typically greater than 8 Gy, however, there is
mounting evidence to suggest the α/β of prostate cancer is low; in the range of 1.2
to 3.9 Gy (Brenner et al. 2002, Kal et al. 2003; Wang et al. 2003). If this α/β is
correct, then the prostate is likely to be particularly sensitive to dose rate effects.
The α/β ratios and corresponding α and β values used in this thesis are taken from
values reported in the literature, and are given in table 2-1 below.
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Table 2-1 Reported radiosensitivity parameters α and β for prostate carcinoma.

A low α/β value of 1.5 Gy was first reported by Brenner and Hall in 1999. The
value is based on compiled clinical data of prostate tumour control in external
beam radiotherapy (EBRT) and permanent seed implants. This work has been
linked with extremely low radiosensitivity (α ~ 0.04 Gy-1) and unrealistically low
clonogenic cell numbers (in the range of 10 to 100). Wang et al. (2003) have also
analysed several reported clinical studies and found α/β = 3.1 Gy. This study
takes into account the repopulation of prostate tumour cells, which resolves the
issue of extremely low α values and clonogenic cell numbers previously reported
by Brenner and Hall (1999). The potential doubling time for prostate cancer has
been reported as between 16 and 170 days with a mean of 42 days. Wang has also
taken repopulation into account for LDR permanent seed implants where the
treatment is over 200 days. Repopulation is generally neglected for EBRT since
treatment time is usually 5-6 weeks.
These estimates have used EBRT in combination with low and high dose rate
brachytherapy to obtain the variations in dose per fraction data necessary to model
both the α and β values. This combined-modality data introduces uncertainties
due to the comparison of the homogeneous dose distributions of EBRT with the
highly inhomogeneous brachytherapy dose distributions.
More recent clinical trials comparing external beam only fractionation effects
have also provided further support for a low α/β of prostate cancer. Arcangeli et
al. (2010) and Norkus et al. (2009) have both demonstrated a therapeutic gain for
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hypofractionated

treatments

versus

conventional

fractionation

schemes.

Theoretically hypofractionation of prostate treatments will only achieve
therapeutic gain if the α/β of the prostate is lower than the surrounding normal
tissue.
Despite the mounting evidence in support of a low α/β for prostate cancer, and
subsequently for specific α and β values, care should still be taken when choosing
an α/β for radiobiological modelling purposes until more precise calculations of α
and β values are available. In chapter 4 the effect of the radiosensitivity
parameters α and β on the radiobiological model is determined.

2.6.3.2 Half Time for Repair in Prostate Carcinoma
Another important parameter in radiobiological modelling is the half-time of
repair of sublethal damage (T1/2). This parameter is determined by estimating
values that best describe cell survival curves of irradiated cell lines (Brenner &
Hall, 1991, Fowler et al. 2004, Wang et al. 2008). It has a large uncertainty (in the
range of 0 to 90 minutes for human tumours) due to the varying environmental
conditions of the cells. Brenner and Hall (1991) report the most probable value for
the repair half-time for human tumours is 20 min. Wang et al. (2003) compared
clinical data from brachytherapy and external beam radiotherapy treatments to
report the best estimated value for the repair half-time of cancerous prostate cells
to be 16 min. A recent in vitro study by Wang et al. (2008) on DU-145 prostate
cancer cells has the repair-half time at 23 min.
Although most studies use only a single repair half-time, it has been well
documented that repair of sublethal damage is likely to be not monoexponential,
but comprised of multiple half-times of repair. The most accurate representation
of reality occurs when a continuum of changing repair half-times is used in
modelling. Fowler et al. (2004) report that the best compromise between accuracy
and calculation complexity occurs when two repair half-times are used. Analysis
of the available data on the repair half times of normal tissues gives a median of
0.3 hours for the fast repair component and 4 hours for the slow repair component
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with a ratio of 50:50 (Fowler et al. 2004). The in vitro study of DU-145 prostate
cancer cells by Wang et al. (2008) found evidence a small portion of radiation
damage repairing with a large half-time of 1.6 hours, with the half-time for the
fast component being 0.3 hours.

2.6.4 Clinical Implications
More research is required to determine whether radiobiological effects due to the
pattern of applied dose exists in vivo and whether temporal dose manipulation has
any benefit clinically. If the temporal pattern of applied dose has a clinical impact,
algorithms could be incorporated throughout treatment planning to optimise not
only the spatial distribution of dose but also the temporal distribution.
As discussed previously, temporal effects have been investigated in the literature
for treatments that exhibit high dose gradients and/or long fraction times such as
IMRT, Tomotherapy, Cyberknife and stereotactic radiotherapy. Another area of
interest is brachytherapy (Manning et al., 2001; Arnfield et al., 2002) where,
similar to modulated external beam treatments, the dose rate at any reference point
in the target volume varies widely. This is due to the steep fall off of dose with
distance from the source. Manning et al. (2001) evaluated the cell survival
fraction for two reference points in a planar brachy implant. The two points were
in areas of equal total dose (10Gy), but were calculated to have surviving fractions
that differed by as much as one order of magnitude.
Keall et al. (2008) looked at the temporal effects for treatments involving
respiratory gating. Respiratory gating is a technique in which the beam is turned
on and off at a certain point in the patient’s breathing cycle. This is beneficial in
reducing treatment margins due to tumour motion, but increases the overall
fraction time due to the intermittent radiation delivery. Keall et al. (2008)
performed in vitro experiments on V79 Chinese Hamster lung fibroblast cell line
(α/β = 10 Gy, repair half-time 24 minutes), to evaluate the effect on cell survival
for standard conformal radiotherapy and IMRT versus gated CRT and gated
IMRT. Survival fractions were found to be comparable for gated CRT and gated
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IMRT with the same overall treatment time. This indicates the overall treatment
time is the main factor influencing effectiveness of respiratory treatments rather
than temporal variations in dose. This is possibly due to the low beta component
in the lung cell line used.
In summary, the impact of the temporal pattern of dose delivery in radiotherapy
requires further investigation,
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3 METHODOLOGY
This chapter outlines the methods and materials used for the acquisition and
manipulation of data throughout the whole of this thesis.
3.1

Overview of MATLAB and CERR

The MATLAB (Matrix Laboratory, produced by The Mathworks Inc)
programming environment, and the add-in program CERR (Computational
Environment for Radiotherapy Research, Deasy et al. 2003) were used
extensively throughout this project. MATLAB is a high-level graphical analysis
and numerical computing program, which uses fourth generation computer
programming language and can be linked to JAVA, FORTRAN, C, C++ and
Visual Basic programs. MATLAB allows the manipulation of large volumes of
data, the plotting of functions and data, implementation of algorithms and creation
of graphics and graphical user interfaces (GUI).
CERR is a MATLAB based ‘open source’ program that was designed to make
inter-institutional radiotherapy treatment planning research more feasible. CERR
facilitates the importation of DICOM or RTOG radiotherapy treatment plans into
MATLAB. The different categories of information of a radiotherapy plan are
stored in different elements of a single MATLAB cell array and can be easily
accessed. The compact representation of the treatment plan archive reduces code
length and complexity. Once a plan has been converted into CERR format, it can
be analysed either graphically or via programmed manipulations. The graphical
features and tools of CERR include: a graphical interface to display computed
tomography images, structure contours, and the dose distribution, tools for editing
or creating contours, and plan analysis tools such as dose volume and dose surface
histograms, tumour control probability (TCP) and normal tissue complication
probability (NTCP).
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3.2

Extraction of the temporal dose histories

In order to determine the effect of the temporal pattern of dose distribution in
clinical situations, the temporal dose history for each individual voxel (discrete
Cartesian volume element representing dose or image information) of a structure
is required. Each voxel will have its own individual dose history based on the
voxel’s location in the PTV, the fluence of the treatment beams, the weighting of
each of beam, the order of beam delivery, and the time over which the dose is
delivered. To obtain the dose history of individual voxels, the CT, structure
contours and dose information of patient treatment plans were DICOM-exported
from the treatment planning system one beam at a time.
The 3D conformal prostate treatment plans used throughout this thesis were
planned using the Xio® treatment planning system (Elekta; CMS Software,
Maryland Heights, MO). All plans had six fields with fixed gantry angles [125o,
90o, 40o, 320o, 270o and 235o using the angle definition of the International
Electrochemical Commission (IEC) (IEC, 1997)]. The IMRT cases were planned
using the Monaco® Monte-Carlo based treatment planning system (Elekta; CMS
Software, Maryland Heights, MO). All plans had seven fields with fixed gantry
angles (150o, 100o, 50o, 0o, 310o, 260o and 210o). The convention of naming the
beams used throughout this thesis corresponds to the order in which beams are
delivered clinically in the department; beginning with the left posterior field (125o
or 150o) and moving anti-clockwise around the patient. Table 3-1 below gives the
beam names used for 3DCRT and IMRT treatment plans and the corresponding
gantry angle.

Table 3-1 Beam naming convention used for 3DCRT and IMRT prostate plans.

The DICOM files for each treatment beam were imported into MATLAB via
CERR. Figure 3-1 below shows the beam-by-beam dose contributions to the
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resulting clinical dose distribution for a six-field 3DCRT treatment plan. The dose
to every voxel in the PTV was extracted for each treatment beam, and input into a
dose array in MATLAB. The dose array contained zeros for every second element
in order to mimic the alternating ‘beam on’ and ‘beam off’ periods that are
symptomatic of 3DCRT and static IMRT treatments. Note that this ignores
variations in dose-rate during delivery of each individual beam. For 3DCRT,
dose-rate will be constant across all voxels during a beam (ignoring variations on
the time-scale of radiation pulses). For IMRT delivery, the dose-rate will vary
during a beam as multi-leaf collimators (MLCs) move to enable modulated
fluence. Detailed knowledge of intra-beam dose-rate variations would require
access to dose arrays for all segments defining a beam and this information is not
available in the treatment planning systems used. The approximation has been
made here that dose-rate during each IMRT beam delivery is constant.

Figure 3-1 Beam by beam dose distributions in CERR of a six field prostate 3DCRT
treatment plan exported from the Xio® treatment planning system. The target volume is
shown outlined in red. The naming convention of the beams corresponds to the order in
which beams are delivered clinically; beginning with the left posterior field (125o or 150o)
and moving anti-clockwise around the patient.
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The calculation of G in the model requires a timing sequence that corresponds to
the ‘beam-on’ and ‘beam-off’ times in a treatment fraction. Separate time files
were created for the 3DCRT and IMRT plans to correspond to the beam-on and
beam-off times indicative of these treatments. In order to obtain typical beam-on
and beam-off times for the IMRT cases, the delivery of five clinical prostate
IMRT treatments were timed, and the average beam on and beam off duration
within a typical prostate IMRT fraction was determined. The average ratio of
beam-on to beam-off time was found to be 1.08 and is shown in table 3-2. A set of
four standard time arrays with total treatment times ranging from 5 to 30 minutes,
were then created to apply to the dose arrays. The standard times were created to
have a similar beam on to off ratio as the measured clinical prostate plans. Figure
3-2 shows the dose histories for four randomly selected voxels in the PTV of an
IMRT plan. The standard time of 5 minutes has been applied to the doses. The
order in which the doses are delivered to the voxel and the overall treatment time
can therefore be manipulated to predict the distribution of biological effect and
overall effect on a structure.
The timing sequence to apply to the 3DCRT cases was calculated based on the
average number of MUs for each beam (‘beam-on time’), delivered at a dose rate
of 600 MU per minute, and the time it takes the gantry and collimator to rotate
into position between beams (‘beam-off time’), measured to be 0.5 seconds per
degree of gantry rotation. The average time for a 3DCRT treatment to be
delivered was calculated to be 2.6 minutes.
Table 3-2 Fraction treatment times and the beam on to off ratio for 5 IMRT prostate
patients.
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Figure 3-2 Example dose histories for four randomly selected voxels in the PTV of an IMRT
treatment plan. The order in which the doses are delivered to the voxel, and the overall
fraction time can be manipulated to determine the subsequent effect on cell survival in the
voxel.

3.3

Calculation of cell survival

Cell survival for each individual voxel was calculated using the linear quadratic
formalism, including protraction factor, G, described earlier in section 2.3
(equation 2.5). A numerical integration method was used to approximate the
general form of G (equation 2.6). The total fraction time is divided into segments
with the dose rate calculated for each segment, and then summed over the inner
and outer integrals. The input parameters for the calculation are the corresponding
dose and time values extracted from clinical plans, the α and β radiosensitivity
parameters and lambda, the constant related to the half-time for repair.
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4 INFLUENCE OF INPUT PARAMETERS ON RADIOBIOLOGICAL
MODEL

4.1

Overview

Radiobiological modelling can be a useful tool in predicting the biologic outcome
of radiotherapy treatments on tumour and normal tissue cells. The accuracy of
these models relies upon precisely known input parameters. As discussed
previously in chapter 2, prostate carcinoma in particular suffers from a lack of
accurate radiobiological parameter data. In this chapter the effect of input
parameters on the model is investigated, covering the range of reported α, β and
T1/2 for prostate carcinoma and typical prostate external beam treatment times.
The numerical solution to the protraction factor, G, is also compared with an
analytical solution.

4.2

Method

In this section a voxel dose history, typical of a seven-field IMRT fraction of 2 Gy
was used for all calculations. To quantify how sensitive the model is to the input
parameters, calculations for G, S and EUD were compared to calculations for an
instantaneous delivery.
4.2.1 Alpha and Beta Values
To investigate the influence the α and β values have on our model, the percentage
difference in S and EUD, between an instantaneous dose delivery and that with
temporal effects modelled was calculated:

⎛ S − SG ⎞
⎛ EUDA − EUDG ⎞
%DiffS = 100 × ⎜ A
⎟ %DiffEUD = 100 × ⎜
⎟
EUDA
⎝ SA ⎠ ,
⎝
⎠
Subscript G indicates temporal effects were modelled by using the numerical
€
€
solution to protraction factor G in the calculation. Subscript A indicates an acute
(instantaneous) treatment delivery is assumed (i.e. G = 1). A repair half-time of 16
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minutes and a treatment time of 5 minutes was used in the calculations. The
values of α and β used were taken from a range of values reported in the literature
(see section 2.7.3.1) and are given previously in table 2-1. The α/β ratio ranged
from 1.2 Gy to 10 Gy to incorporate the large range of reported values and the
hypothesised tumour α/β. The subsequent percentage difference in EUD was also
calculated.

4.2.2 Half-Time for Repair
The effect of half-time for repair of sublethal damage (T1/2) on the radiobiologic
model was determined by calculating the percentage difference in G, S and EUD
between an instantaneous delivery of dose (subscript A) and that with temporal
effects modelled (subscript G):

⎛ G − GG ⎞
%DiffG = 100 × ⎜ A
⎟
⎝ GA ⎠
%Diff S and EUD were calculated as above. A treatment time of 5 minutes, and
€
an alpha beta ratio of 3.1 Gy (α = 0.15 Gy-1, β = 0.0484 Gy-2) were kept constant
in the calculations. The values used for T1/2 ranged from 5 to 90 minutes to
incorporate values reported in the literature for prostate and other tumours (see
section 2.7.3.2). The subsequent percentage difference in EUD was also
calculated. The effect of prostate carcinoma having two components of repair was
investigated by calculating the EUD using Tfast=0.3 hours and Tslow=1.6 hours
with a ratio of 50:50 in the calculation for G.

4.2.3 Treatment Time and Dose
The influence of individual fraction times and the dose per fraction was
investigated for G, S and EUD for fractions varying from 0 to 30 minutes, and
doses of 2 Gy up to 8 Gy per fraction. Radiobiological parameters were kept
constant (α/β = 3.1 Gy, T1/2 = 16 minutes).
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4.2.4 Numerical calculation of G
To check the accuracy of the numerical solution for the protraction factor, G, the
calculations of G and subsequent cell survival, S, were compared to those
predicted by the analytical solution (equation 2.8) first reported by Wang et al.
(2003). A numerical approach was developed for this study to enable
incorporation of changes in dose-rate within delivery of each beam. This will
accommodate progression of this study when dose distributions per beam segment
are available or dose-rate variations are known via other means. As a constant
dose-rate is being assumed for this study, it is possible to compare this approach
with an exact solution.

4.3

Results

4.3.1 Alpha and Beta Values
Figure 4-1 shows the percentage difference in S for a range of α/β (specific α and
β values are given in table 2-1 previously). The largest difference of 1.6% was
observed for α/β = 3.1 Gy (Wang et al. 2003). This is due to the large β
component (0.0484 Gy-2) associated with this ratio compared to the other ratios
used. Figure 4-2 shows the dependence of temporal effects (%Diff S) on the β
2

component alone ( S = e − βGD ). As the β component increases so too does the
influence of temporal effects on cell survival. This is due to the increased
potential for sublethal damage repair for tissues exhibiting large β values.
€
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Figure 4-1 Percentage difference in S between an instantaneous treatment delivery and S
with temporal effects included, for a range of reported prostate alpha and beta values.
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Figure 4-2 Percentage difference in S when the beta component is varied with treatment
time.
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Figure 4-3 Percentage difference in EUD when alpha beta ratio and treatment time is varied.

4.3.2 Half Time for Repair
Figure 4-4 shows the percentage difference in G and S as the half-time for repair
of sublethal damage is varied. Large percentage differences in G are observed at
short repair half-times; 7.5% difference at T1/2 = 16 minutes, which translates to a
difference of 1.6% in S. This is in agreement with previous studies that have
shown that tissues are sensitive to temporal dose effects when the delivery time is
comparable to the repair time (Bewes et al. 2012). Figure 4-5 shows the
subsequent percentage difference in EUD with varying repair half-times and
treatment times. α/β is kept constant at 3.1 Gy. For T1/2 = 16 minutes and a
treatment time of 5 minutes, the difference in EUD is 3.4%.
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Figure 4-4 Percentage difference in G and S with varying repair half-times. α/β = 3.1 Gy,
treatment time = 5 minutes.
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Figure 4-5 Percentage difference in EUD for a range of T1/2values, α/β = 3.1 Gy.
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4.3.3 Treatment Time and Dose
Figure 4-6 and 4-7 show the influence of treatment time and dose per fraction
when α/β and T1/2 are kept to a constant 3.1 Gy and 16 minutes respectively. At
large fraction times the percentage difference between an acute and protracted
treatment is increased due to the larger amount of sublethal damage repair. At 30
minutes the percentage difference in G is 32.6%. This results in a percentage
difference of 7% and 13.1% for S and EUD respectively. At clinically relevant
treatment times for prostate EBRT (approximately 5 minutes), the percentage
difference in S and EUD is less than 5% for a single fraction. Over the course of
treatment this percentage difference in S will be magnified depending on the
number of fractions. The percentage difference in S exhibits a large dependence
on the dose per fraction (figure 4-7), due to the exponent of the dose-squared term
2

( S = e − βGD ). At 2 Gy per fraction the difference is 1.6%, as the dose per fraction
increases to up to 8 Gy per fraction the percentage difference can be as large as
28% for a single fraction.
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Figure 4-6 Percentage differences in G, S and EUD using parameters of α/β = 3.1 Gy, T1/2=
16 minutes, for varying treatment times.
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Figure 4-7 Percentage difference in S and EUD using parameters of α/β = 3.1 Gy, T1/2= 16
minutes, fraction time = 5 minutes, for varying dose per fraction.

4.3.4 Numerical calculation of G
The results given in table 4-1 are for a dose history typical of a seven-field IMRT
treatment. The total dose to the voxel is 2 Gy. Treatment time was varied from 5
to 30 minutes and an alpha beta ratio of 3.1 Gy and a repair half-time of 16
minutes was used.
Table 4-1 Values for G and S when G is calculated with a numerical and analytical method.

At small fraction times, the difference in the calculated values for G is less than
2%. As the fraction time increases so too does the percentage difference in G. At
30 minutes the difference is 3.1%. Despite the large differences in the calculated
protraction factor, cell survival calculation incorporates G via an exponent and so
surviving fraction for both calculation methods remains within 1% for all fraction
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times up to 30 minutes. Larger discrepancies in S are exhibited as the dose per
fraction is increased (figure 4-8). A difference of 6.7% is seen for an 8 Gy per
fraction dose delivered over 30 minutes. The consequent effect on EUD was
determined (figure 4-9). The percentage difference in EUD was found to be with
2% for all scenarios tested.
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Figure 4-8 Percentage differences in cell survival, S, between the numerical and analytical
methods for calculating G, when dose per fraction is increased up to 8 Gy.
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Figure 4-9 Percentage difference in EUD for the two methods of calculating G.

4.4

Discussion

These results confirm that biological effects in tumours such as prostate cancer,
with a reported low α/β ratio (Brenner et al. 2002, Kal et al. 2003; Wang et al.
2003) and a short half-time for sublethal damage repair (Wang et al. 2003, Wang
et al. 2008), will be sensitive to the intra-fraction temporal effects introduced with
modulated external beam treatments. The radiobiological model used has shown a
high sensitivity to α/β (in particular, the β value), T1/2, treatment time and dose.
Figure 4-4 shows that temporal effects are increased when the half-time for repair
is comparable to the treatment time.
The values reported by Wang et al. (2003) (α/β = 3.1Gy and T1/2 = 16 minutes)
were chosen as the parameters to use throughout the rest of this thesis. These were
chosen as they are the reported values for prostate cancer that are most sensitive to
temporal effects (Figure 4-1 and 4-4). Therefore, results derived henceforth are
exclusive to these parameters. Figure 4-6 shows the difference to be expected in S
and EUD, between an instantaneous delivery and with temporal effects modelled,
is approximately 1.6% and 3% respectively, for a single fraction. Over the course
of the entire treatment, this difference in S will be magnified.
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The numerical solution to G was found to be in agreement to the analytic solution
at small doses per fraction. For the standard scenario of a 2 Gy/fx treatment the
difference in S and EUD is less than 1% for all treatment times. Worst-case
scenario is for dose of 8 Gy/fx over a 30 minute treatment time, the percentage
difference in S is 7%, although the difference in EUD remains below 2%. Our
numerical solution for G was therefore found to be appropriate for the purposes of
this thesis. The analytical solution tested is only applicable to the specific case of
constant dose-rate over fixed time intervals. The advantage of a numerical
solution is that it can be easily applied to this and any other arbitrary temporal
dose history. In general, for an arbitrary temporal dose history, an exact analytical
solution would not exist.
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5 INFLUENCE OF THE TEMPORAL PATTERN OF DOSE DELIVERY
ON BIOLOGICAL EFFECT

5.1

Overview

Historically intra-fraction temporal dose effects in external beam radiotherapy
have been assumed negligible due to the relatively short fraction times of
conformal radiotherapy. With the introduction of more complex treatment
techniques, such as IMRT and Cyberknife, fraction treatment times can become
protracted, reducing their biological effectiveness (Mu et al., 2003; Bewes et al.,
2008; Wang et al. 2003). Furthermore, there is mounting evidence to suggest the
intra-fraction sequence of dose delivery has an effect on cell kill. The optimal way
to deliver dose for maximum cell kill is instantaneously. Due to the nature of
external beam therapy this is not practically achievable, and cells in a voxel will
see a variable dose per beam. In a paper by Altman et al. (2006) it was
demonstrated via radiobiological modelling that cell kill was able to be
maximised or minimised based on the pattern of the dose applied to a single
voxel. Maximum cell kill was found to occur when the highest doses are applied
to the middle of the treatment, and the lowest doses at the beginning and the end
(‘Pyramid-shape’). Minimisation of cell kill is achieved by concentrating the
lowest doses in the middle of the treatment period (‘V-shape’). These results were
confirmed with follow up in vitro studies (Altman et al. 2009). The pyramid shape
is the dose pattern which best approximates the ideal dose pattern of an
instantaneous dose delivery to the tumour.
Ultimately, temporal optimisation could be implemented into treatment planning
to take advantage of these time-dose effects. The goal for external beam
treatments would be to optimise the MUs and MLC position as a function of beam
angle to deliver the pyramid shape dose history to the tumour, while delivering the
V-shape dose history to the surrounding normal tissues. The implementation of
temporal optimisation into treatment planning is not a trivial exercise, and to date,
previous studies have only considered temporal effects in a single voxel. Whereas
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in a typical radiotherapy treatment plan there exists a large array of voxels, which
all exhibit a unique dose history depending on their location in the patient
geometry and the treatment plan generated. In this study we will extract the
individual dose histories from clinical external beam treatment plans to evaluate
the influence of temporal effects over the whole target area, rather than simply a
single voxel.
There are three main aims of this chapter: 1) to use the extracted dose histories to
predict the influence of temporal effects over the entire PTV of clinical prostate
external beam plans; 2) to investigate the pattern of dose which gives the
maximum and minimum cell kill and 3) to optimise cell kill in each voxel of
clinical treatment plans and evaluate the biological effect on the prostate.

5.2

Method

For all calculations in this chapter the LQ parameters used are α/β = 3.1 Gy (α =
0.15 Gy-1, β = 0.0484 Gy-2), and a 16 minute repair half-time (Wang et al. 2003).
The standard fraction times for 3DCRT (2 minutes) and IMRT (5 minutes) were
used in the calculations. Unless otherwise stated, the prescription dose is 74 Gy in
2 Gy fractions.
5.2.1

Influence of temporal effects on biological outcome

The influence of temporal effects in clinical 3DCRT and IMRT external beam
treatments was investigated by calculating cell survival and BED with, and
without temporal effects included. For five 3DCRT and five IMRT treatment
plans, the dose contribution to each voxel in the PTV, from each treatment beam
was extracted as described in section 3.3. Cell survival and BED were then
calculated for each voxel in the PTV from equations 2.9 and 2.10. The percentage
difference in cell survival and BED when temporal effects are modelled,
compared to the assumed instantaneous delivery, was then determined for each
voxel:
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⎛ S − SA ⎞
⎛ BEDG − BEDA ⎞
%DiffS = 100 × ⎜ G
⎟ , %DiffBED = 100 × ⎜
⎟
BEDA
⎝ SA ⎠
⎝
⎠
Where the subscript G indicates temporal effects were modelled by using the
€
€
protraction factor G in the calculation. Subscript A indicates an acute
(instantaneous) treatment delivery is assumed (i.e. G=1). To evaluate the
effectiveness of the treatment over the whole PTV, the EUD (equations 2.11 and
2.12) was also calculated with temporal effects (EUDG) modelled and for an acute
treatment delivery (EUDA).
The distribution of %DiffS within the PTV was then viewed using the
visualisation toolbox in CERR for each patient. This was achieved by writing
MATLAB code to add the %DiffS values as a new dose distribution to the
patient’s CT scan and setting all values outside the PTV equal to zero.

5.2.2 Optimisation of cell kill in single voxels
The influence of the sequence of dose delivery on cell survival in a single voxel
was investigated by manipulating the dose histories of voxels in the PTV of
clinical 3DCRT and IMRT prostate treatment plans. The individual dose histories
for each voxel were extracted and the cell surviving fraction and BED were
calculated for every possible arrangement of the dose history. The standard timing
sequences of a typical 3DCRT and IMRT treatment fraction were used in the
calculation, as described in chapter 3. The dose histories giving the maximum and
minimum cell kill were then plotted for 10 randomly selected voxels. The
percentage difference between Smax (minimum cell kill) and Smin (maximum cell
kill) was also calculated, and normalised to the original dose arrangement, Sorig.
The percentage difference in BED was also calculated:

⎛ S − S ⎞
⎛ BED − BED ⎞
min
max
min
⎟⎟ , %DiffBED = 100 × ⎜⎜
⎟⎟
%DiffS = 100 × ⎜⎜ max
S
BED
⎝
orig
⎠
⎝
orig
⎠

€

€
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5.2.3 Unrestricted optimisation of cell kill over the entire PTV
To quantify the biological effect of temporal optimisation on the entire PTV, the
array of cell survival fractions corresponding to the pyramid shape dose delivery
in each voxel (Smin) was then used to calculate the EUD for the prostate (EUDmax).
This was compared to the EUD calculated with the original dose arrangement
(EUDorig) and when the dose is arranged in the V-shape pattern (EUDmin). In these
cases, the dose histories of all voxels are considered to be independent – the
optimisation is not restricted by the practicalities of dose delivery. In Chapter 6,
we shall consider optimisation of beam order which maintains the dependence of
individual voxel dose histories. The effect of changing the dose per fraction was
also investigated.
5.3

Results

5.3.1 Influence of temporal effects on biological outcome
Tables 5-1 and 5-2 show the average and range (across all dose calculation voxels
in the PTV) of the percentage difference in cell survival for each treatment plan
evaluated. In a single 3DCRT fraction there is an average percentage increase in
cell survival of 0.65% when temporal effects are considered. This corresponds to
an increase of 27.3% in cell survival over the whole treatment course (37
fractions). For an IMRT fraction, the average percentage increase in S was found
to be 1.7% when temporal effects are considered. Over the whole treatment
course, this becomes on average an 87.6% increase in cell survival. The
consequent effect on BED and EUD is given in tables 5-3 and 5-4. The average
percentage difference in BED and EUD was found to be -1.3% for the 3DCRT
treatment plans. For the IMRT treatment plans the percentage difference in BED
was found to be on average -3.2% in each voxel. Considering the entire PTV (i.e.
EUD) the treatment was found to be 3% less effective when temporal effects are
considered.
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Table 5-1 The average difference in cell survival across all voxels in the PTV for the five
3DCRT treatment plans.

Table 5-2 The average difference in cell survival across all voxels in the PTV for the five
IMRT treatment plans.

Table 5-3 Percentage difference in BED and EUD for the whole PTV when temporal effects
are modelled in 3DCRT treatment plans.

Table 5-4 Percentage difference in BED and EUD for the whole PTV when temporal effects
are modelled in IMRT treatment plans.

For the IMRT treatment plans, %Diff S, or the loss in cell kill due to temporal
effects, was added to the plan in the visualisation toolbox within CERR. Figure 51 shows the distribution of %DiffS in the PTV in the transverse, sagittal and
coronal views for each IMRT patient plan analysed. For patients 1, 3, 4 and 5 the
largest percentage differences are observed to be in the middle of the prostate,
with the anterior and posterior portions exhibiting a smaller percentage difference.
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For patient 2 the largest percentage differences are at the apex of the prostate. This
was investigated further by examining the pattern of the voxel dose histories in
these regions. The dose histories for every voxel in the PTV were categorised into
three groups: (1) those likely to have a V-shape dose pattern, i.e. where the ratio
of the middle dose to the dose at the beginning and end is less than 1, (2) the dose
histories likely to exhibit the pyramid pattern, i.e. where the middle dose is equal
to the maximum dose, and (3) all other possible dose histories (i.e. relatively
homogeneous dose history). Figure 5-2 shows the distribution of the three
categories in the PTV. The pattern of dose was found to correlate somewhat with
%Diff S. Dose histories in the centre of the PTV were generally observed to be a
category 1 or 3 dose history, correlating to the largest %Diff S values. The
majority of voxels were found to be from category 1 or 3. Where category 2 dose
histories are observed (patient 2 and 5) they are generally seen to be in the
superior - posterior region of the prostate.
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Figure 5-1 The distribution of %Diff S within the PTV of five patient IMRT treatment plans.
The red regions indicate a decrease in cell kill due to temporal effects compared to the
prescribed dose.
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Figure 5-2 Distribution of the three dose history categories in the PTV; likely V shape
pattern (blue), pyramid pattern (red), all other possible dose patterns (green).
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The influence of temporal effects on hypofractionated prostate treatments were
investigated by increasing the dose per fraction of the IMRT plans. Four different
dose per fraction schemes were analysed, ranging from 2 Gy/fx to 8 Gy/fx. These
values were chosen as they encompass the hypofractionation schemes in use for
prostate external beam treatments (see section 2.2.2.3). Table 5-5 shows the
average percentage difference in S and EUD when temporal effects are included.
%Diff in S and EUD is seen to increase with increasing dose per fraction.

Table 5-5 Temporal effects for various hypofractionated treatment schemes.

5.3.2 Optimisation of cell kill in single voxels
In all voxels visually analysed, the maximum cell kill (Smin) was found to be when
the dose history is arranged in a pyramid shape arrangement. The minimum cell
kill (Smax) was found to be when the dose is arranged in the V-shape pattern for all
voxels analysed. Figures 5-3 and 5-4 show the optimal and least optimal
arrangement of doses for a voxel in a 3DCRT and an IMRT treatment plan
respectively.
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Figure 5-3 a) Optimal order of applied dose (S=0.6086) b) least optimal order of applied dose
(S=0.6091) for the 3DCRT plan.

Figure 5-4 a) Optimal order of applied dose (S=0.5923) and b) least optimal order of applied
dose (S=0.5943) for the IMRT plan.
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Table 5-6 Average percentage difference in S and BED between the optimal and least
optimal dose arrangements in five 3DCRT treatment plans

Table 5-7 Average percentage difference in S and BED between the optimal and least
optimal dose arrangements in five IMRT treatment plans

In this section %Diff S is the difference in cell survival for the optimal and least
optimal dose arrangements and represents the potential for temporal optimisation.
%Diff S ranges from on average 0.7% to 5.0% for the 3DCRT plans and from
4.3% to 27.1% for the IMRT plans, indicating temporal effects are more
prominent in modulated treatments, and have a greater potential for optimisation.
To investigate the areas which are most influenced by temporal effects, %Diff S
was added to the IMRT patient treatment plans in the visualisation toolbox within
CERR. Figure 5-5 shows the distribution of %Diff S in the prostate in the
transverse, sagittal and coronal views, for the five plans analysed. For patient 1
the largest differences in %Diff S appear to be in the middle of the prostate.
Patients 2 to 5 generally exhibited larger differences in %Diff S to edges of the
prostate in the superior-inferior and anterior-posterior directions, while the centre
of the prostate has a smaller difference in %Diff S. This suggests the dose
histories of the IMRT plans are more homogeneous at the centre of the PTV.
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Figure 5-5 The distribution of %Diff S within the PTV of five patient IMRT treatment plans.
The red regions indicate the areas with the greatest potential for temporal optimisation.
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5.3.3 Unrestricted optimisation of cell kill over the entire PTV
Table 5-8 and 5-9 give the calculated percentage difference in EUD compared to
the original treatment plan, for the PTV when the optimal and least optimal dose
arrangements are delivered to all voxels. Despite the increased cell kill when dose
is arranged in the ‘pyramid’ pattern as demonstrated in the previous section, the
increase in EUD for the PTV is modest – on average 0.1% for 3DCRT treatment
plans and 0.8% for IMRT treatment plans.

Table 5-8 %Diff in EUD for the 3DCRT treatment plans due to the optimisation of every
voxel dose history.

Table 5-9 %Diff in EUD for the IMRT treatment plans due to the optimisation of every voxel
dose history.

The potential for temporal optimisation was also investigated for increased dose
per fraction schedules. Four different dose per fraction schemes were analysed,
ranging from 2 Gy/fx to 8 Gy/fx. These values were chosen as they encompass the
hypofractionation schemes in use for prostate external beam treatments (see
section 2.2.2.3). Table 5-10 shows the average percentage difference in S and
EUD when the optimal and least optimal dose arrangements are delivered to all
voxels. %Diff in S and EUD is seen to increase with increasing dose per fraction.
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Table 5-10 Increase in the dose per fraction.

5.4

Discussion

In this study we have demonstrated a method to analyse temporal dose effects in
external beam radiotherapy. By extracting the beam-by-beam dose distributions of
clinical treatment plans and using the LQ model to calculate the biological effect
for each voxel in a particular volume we have shown the actual biological effect
of the delivered dose is not uniform over the target volume. Furthermore, the
incorporation of temporal effects reduces the overall treatment effectiveness of 2
Gy/fraction treatments by on average 1.3% for the 3DCRT plans and 3% for the
IMRT plans (when assessed by EUD). The results presented in section 5.3.1
suggest a more direct incorporation of biologic effects into treatment planning is
possible and may be needed. Visualising the distribution of biological effect rather
than just physical dose can provide useful information when analysing the clinical
effectiveness of the treatment plan, for example, areas exhibiting a biological
‘cold spot’ could be boosted by increasing the physical dose, or vice versa, the
dose to a biological ‘hot spot’ could be reduced if it is located in close proximity
to a critical organ.
Figure 5-1 shows the distribution of %DiffS in the PTV in the transverse, sagittal
and coronal views for each IMRT patient plan analysed. Generally the largest
differences in cell survival due to temporal effects were seen to be in the middle
of the prostate, with the anterior and posterior portions exhibiting a smaller
percentage difference. This was investigated further by investigating the pattern of
voxel dose histories in these regions (figure 5-2). The dose histories in the centre
of the PTV were generally found likely to be a V shape or homogeneous pattern.

57

While pyramid shape patterns were found to most likely be in anterior and
posterior portions of the prostate.
The optimisation of dose deposition was found to be in agreement with Altman et
al. (2006). A pyramid shape dose arrangement was found to give the maximum
cell kill while the inverse pattern (V-shape) was found to give the minimum cell
kill. These optimisation patterns are thought to arise due to the nature of cell kill
from radiation damage. As discussed in section 2.1 cell kill consists of three
components: (1) lethal damage, which is irreparable and leads to cell death, (2)
sublethal damage which interacts with previously created sublethal damage to
form lethal damage and (3) potentially lethal damage that can interact later with
sublethal damage to create lethal damage. The pyramid dose shape best
approximates an instantaneous dose delivery and makes the best use of sublethal
damage, that is, the type-3 damage created with the small doses at the beginning
of treatment can interact with the type-2 damage created by the large dose in the
middle of the treatment. Similarly, remaining type-3 damage is able to interact
with the sublethal damage created by the small doses at the end of treatment. The
V-shape in effect wastes the sublethal damage created by the large doses delivered
to the beginning and end of the treatment by not following up with a sufficient
amount of type-2 damage.
On average there was a 2.6% difference in cell survival between the pyramid and
V-shape arrangements in 3DCRT plans and a 15.3% difference in the IMRT
plans. The impact of optimising the temporal dose pattern to every voxel in the
target volume was found to be modest for a typical 2 Gy per fraction external
beam treatment. A 0.1% increase in effectiveness was calculated for the 3DCRT
plans and a 0.8% increase in effectiveness for the IMRT plans. The potential for
temporal optimisation was found to increase with increasing dose per fraction.
This is due to the increase in effect of incomplete repair within the treatment
fraction. For an 8 Gy per fraction hypofractionation schedule, a 1.4% increase in
EUD was calculated. Figure 5-5 shows the distribution of the percentage
difference in cell survival when the dose is arranged in the pyramid and V shape
pattern. This gives an indication of the areas that would benefit most from
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temporal optimisation. In the majority of plans the percentage difference was seen
to be largest at the edges of the PTV, but ultimately, the areas most likely to
benefit from temporal optimisation will depend on the patient anatomy and
individual treatment plan.
All results generated in this chapter were for the standard treatment timings of 2
minutes for the 3DCRT plans and 5 minutes for the IMRT plans. As demonstrated
in chapter 4, as the treatment time increases so to will the potential for temporal
optimisation. The results presented are also limited by the approximations used in
the radiobiological parameters. As shown in chapter 4, intra-fraction temporal
dose effects are highly sensitive to the range of reported radiobiological
parameters for prostate carcinoma. Clearly, accurate values of α, β and T1/2 are
required for accurate modelling of temporal effects and optimisation.
Another assumption in the model is the simplified representation of IMRT
delivery. By ignoring the segmental delivery of dose, we have assumed a constant
dose rate for the delivery of IMRT beams. More accurate modelling can be
performed if the doses per beam segment could be exported from the treatment
planning system used.
Daily setup errors and organ motion will also influence temporal effects in
external beam radiotherapy. The results presented here are based on the dose
delivered to voxels in the CT taken at the time of treatment planning. This CT is a
snapshot of the patient’s internal anatomy at a single point in time. In reality the
patient’s anatomy may change day to day due internal organ motion, or the
change in tumour size over the course of the treatment. In addition, patient
position variations may occur during treatment set-up and delivery. This will have
the effect of ‘blurring’ the impact of temporal effects over the course of the
treatment.
The magnitude of internal organ motion and daily setup errors for prostate EBRT
has been reported in the literature, and is dependent on the local setup,
immobilisation and imaging verification protocols. van Herk et al. (2000) give
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values for the geometric uncertainties of prostate irradiation for a typical patient
population (see table 5-11). Both the average systematic and random errors are
greater than the size of the voxels used in this study (1 x 1 x 2.5 mm) to compute
the temporal effects, suggesting any temporal optimisations could be negated by
geometric shifts. To account for these geometric errors clinically, PTV margins to
apply to the CTV can be calculated. The margins are calculated for a patient
population using the van Herk et al. (2000) formula for specific daily setup
protocols. van Herk et al. calculated that to ensure a minimum dose to the clinical
target volume of 95% for 90% of the patients, the margin around the CTV should
be the sum of 2.5 times the standard deviation of the overall systematic error and
0.7 times the standard deviation of the overall random error. A systematic error
has the effect of shifting the dose distribution with respect to the high-dose region,
whereas, random errors are day-to-day variations that blur the dose distribution.

Table 5-11 Geometric uncertainties of prostate irradiation (van Herk et al. 2000)

Treatment Execution (random errors)
(mm)

Treatment Preparation (systematic errors)
(mm)

Left - Right

Sup - Inf

Ant - Post

Left - Right

Sup - Inf

Ant - Post

Organ Motion

0.9

1.7

2.7

0.9

1.7

2.7

Setup Error

2.0

1.8

1.7

2.6

2.4

2.4

Various authors have investigated the impact of these geometric uncertainties on
treatment outcome. Arcangeli et al. (2004) introduced mean shifts to IMRT
prostate plans and compared the resultant DVH and TCP values for the CTV, and
the NTCP values to the initial planning values. They concluded the prescribed
dose to the CTV was not significantly affected, but observed the shifts to have a
greater effect on surrounding normal tissues.
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Bos et al. have also investigated the effect of setup uncertainties and organ motion
in prostate IMRT plans. Three different treatment techniques were used which
included variations in total dose and margin size. Technique 1 delivered 78 Gy to
PTV 1 (CTV + 10mm margin). Technique 2 delivered 68 Gy to PTV 1 and a
boost of 10 Gy to PTV 2 (CTV + anisotropic margin of 0 to 5 mm). Technique 3
delivered 68 Gy to PTV 1 and simultaneously 78 Gy to PTV 2 (e.g. a
simultaneous integrated boost). Typical setup and organ motion uncertainties were
simulated and the effect evaluated by comparing the new TCP value to the initial
planned TCP. Techniques 1 and 2 were found to be insensitive to geometric
uncertainties, while a small reduction in TCP (up to 2.4%) was found for
technique 3.
These investigations indicate that the effect of geometric uncertainties on the dose
distribution can have a significant effect on the delivered dose to the CTV, and
hence temporal dose effects, but can be minimised by using appropriate margins
and daily imaging techniques.
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6 OPTIMISATION OF BIOLOGICAL EFFECT DUE TO THE ORDER OF
TREATMENT BEAM DELIVERY

6.1

Overview

The nature of external beam radiotherapy means that each voxel in the target
volume will have its own individual dose history based on the location in the
volume, the fluence of the beam, the weighting of each of the treatment beams,
the order of beam delivery, and the total fraction time over which the dose is
delivered. The previous chapter dealt with the theoretical case in which the pattern
of dose to every voxel is optimised. In this scenario, the dose histories of all
voxels were considered to be independent – the optimisation was not restricted by
the practicalities of dose delivery. In reality, all voxels need to be considered
simultaneously to deliver the treatment that gives the optimal outcome when
temporal effects are taken into account. In this section we investigate to what
extent simply altering the order of treatment beam delivery provides biological
optimisation over the whole target area.
6.2

Method

Five 3DCRT prostate plans and five IMRT prostate plans were examined to
determine the biological effect of altering the treatment beam order. The
fractionation schedule for both the 3DCRT and IMRT plans was 2 Gy per fraction
up to 74 Gy. The number of gantry angle combinations is equal to the factorial of
the number of beams in the treatment, i.e. the six-field 3DCRT treatments have
720 possible gantry combinations, and the seven-field IMRT treatments have
5040 gantry combinations. A script was written in MATLAB to calculate the total
EUD (equation 2.10) for the prostate PTV for each gantry angle combination,
taking into account the temporal variations in dose as previously described. The
most effective beam combination, with respect to cell kill in the PTV, is deemed
to be that with the largest EUD. The optimal beam order combination was initially
determined using the standard time files for 3DCRT and IMRT treatments, for all
beam angle combinations. Realistically, each gantry angle combination will have
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a different timing sequence and total fraction time due to the amount of gantry and
collimator rotation required between beams. A MATLAB script was written to
calculate the timing sequence corresponding to each gantry angle combination.
The beam-on times used were from average measured values described in chapter
3. The beam-off times were calculated based on the number of degrees the gantry
is required to move between beams, using a gantry speed of 1 degree per 0.5
seconds. The fraction times varied between 2.6 minutes (combination 1 2 3 4 5 6
or 6 5 4 3 2 1) and 8.1 minutes (3 5 1 6 2 4 or 4 2 6 1 5 3) for the 720-gantry angle
combinations of the 3DCRT treatment plans. The fraction times for all
combinations of the seven IMRT beams varied between 5.2 (combination 1 2 3 4
5 6 7 or 7 6 5 4 3 2 1) and 12 minutes (8 possible combinations).
For the IMRT plans, the dose per fraction was altered to up to 8 Gy per fraction to
analyse the effect of hypofractionation schemes on intra-fraction temporal effects.
This was achieved by scaling the original 2 Gy per fraction doses. The number of
fractions used in the calculation of cell survival was reduced to keep the BED
approximately constant. The beam-on times of the timing sequences were scaled
by the same amount as the doses to account for the longer beam on times for
larger doses per fraction.

6.3

Results

6.3.1 Constant treatment time
The results for the optimal beam order combination when a constant treatment
time is used for all beam combinations are given in tables 6-1 and 6-2. For the
majority of 3DCRT patients the maximum EUD for the prostate was found to be
for the beam combination of 1 2 3 4 5 6, that is, with the left posterior field (125o)
delivered first, followed by the 90o, 40o, 320o, 270o and 235o fields respectively.
Patient 3 and 4 were the exceptions, with the optimal beam orders of 6 4 5 2 3 1
and 1 3 2 5 4 6 respectively. The increase in EUD due to optimising the beam
order was calculated to be 0.1% for the 3DCRT plans. The optimal beam order
combination for IMRT plans appears to be patient and plan specific. Each IMRT
plan tested had a unique optimal beam order combination (table 6-2). On average
63

there was a 0.8% difference in EUD between the optimal and least optimal beam
order.
Table 6-1 Optimisation of beam order for the 3DCRT treatment plans, using the standard
time file in the calculation.
Patient
Max EUD (Gy)
Beam order - max EUD
Min EUD (Gy)
Beam order - min EUD
%Diff (max,min)

1

2

3

4

5

72.3
123456
72.2
351624
0.1

71.5
645231
71.4
531642
0.1

72.2
123456
72.2
426153
0.1

70.0
132546
69.9
531642
0.1

70.4
123456
70.3
426153
0.1

Table 6-2 Optimisation of beam order for the IMRT treatment plans, using the standard
time file in the calculation.
Patient
Max EUD (Gy)
Beam order - max EUD
Min EUD (Gy)
Beam order - min EUD
%Diff (max,min)

1

2

3

4

5

74.9
7635214
74.1
3247165
1.1

76.5
3142756
76.0
3736154
0.6

75.3
1623574
74.5
5274163
1.0

72.9
763251
72.6
257416
0.5

75.0
1234576
74.6
4271635
0.6

6.3.2 Modified treatment time depending on beam combination
In this section the timing sequence and overall total fraction times were modified
in the calculation of EUD, depending on the beam order combination. The results
for the 3DCRT treatment plans are given in table 6-3. For all patients the
maximum EUD for the prostate and hence optimal beam delivery order with
respect to cell kill in the PTV, was found to be for the beam combination of 1 2 3
4 5 6. This beam combination delivers treatment in a continuous arc around the
patient and hence delivers the dose in the quickest overall fraction time, as the
amount of gantry rotation between beams is minimised. For all patients the least
optimal beam delivery order is seen to be for the combination which gives the
largest treatment fraction time – 4 2 6 1 5 3. The average difference in EUD
between the optimal and least optimal combination was 3.6% for the five
treatment plans. Figure 6-2 shows the distribution of EUD values for the 3DCRT
plans for all beam angle combinations.
Table 6-4 gives the results for the five IMRT patient treatment plans. Similarly to
the conformal results the maximum EUD is found to be for the beam order
combination that gives the shortest fraction time (7 6 5 4 3 2 1). The average
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percentage difference between the optimal and least optimal combination was
4.4% for the five IMRT treatment plans. Figure 6-3 shows the distribution of
EUD values for the IMRT plans for all beam angle combinations.
Results for the IMRT plans at larger doses per fraction are given in tables 6-5, 6-6
and 6-7. Overall the largest EUD is seen to be for the gantry combination giving
the fastest fraction time; either 1 2 3 4 5 6 7 or 7 6 5 4 3 2 1. Interestingly, the
optimal beam order for patient 2 deviated from this pattern at 6 and 8 Gy per
fraction. Figure 6-1 shows the beam order, which gives the maximum EUD for
patient 2 at 8 Gy per fraction. The percentage difference between the maximum
and minimum EUD increases for large doses per fraction. The average percentage
difference in EUD for the five patients was 6.1%, 6.9% and 7.5% for the 4, 6 and
8 Gy doses per fraction respectively. Figures 6-2 and 6-3 show the frequency of
EUD values across all beam angle combinations for the 3DCRT and IMRT plans
respectively. The correlation of EUD and overall treatment time for patient 1 is
shown in figure 6-4 and 6-5 for the 3DCRT and IMRT treatment plans. EUD is
seen to decrease with increasing fraction time. The correlation of EUD with
treatment time for IMRT patient 2, at 8 Gy per fraction shows the maximum EUD
is for a treatment time of 14.6 minutes. The percentage difference in EUD
between the maximum EUD and the EUD for the fastest treatment time is 0.02%.
Table 6-3 Results for the five 3DCRT treatment plans analysed.
Patient

1

2

3

4

5

Max EUD (Gy)
Beam order - max EUD
Fx time (min) - max EUD
Min EUD (Gy)
Beam order - min EUD
Fx time (min) - min EUD
%Diff (max,min)

72.1
123456
2.6
69.5
426153
8.1
3.6

71.3
123456
2.6
68.8
426153
8.1
3.6

73.7
123456
2.6
71.1
426153
8.1
3.7

69.8
123456
2.6
67.5
426153
8.1
3.4

71.8
123456
2.6
69.2
426153
8.1
3.6

Table 6-4 Results for the five IMRT treatment plans.
Patient
Max EUD (Gy)
Beam order - max EUD
Fx time (min) - max EUD
Min EUD (Gy)
Beam order - min EUD
Fx time (min) - min EUD
%Diff (max,min)

1

2

3

4

5

76.6
7654321
5.2
73.2
4527163
12.0
4.6

78.2
7654321
5.2
75.0
5261734
12.0
4.2

76.9
7654321
5.2
73.6
4527163
12.0
4.4

74.7
7654321
5.2
71.7
4527163
12.0
4.1

76.9
7654321
5.2
73.5
5361724
12.0
4.5
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Table 6-5 IMRT optimal beam order results - 4 Gy per fraction.
Patient

1

2

3

4

5

Max EUD (Gy)
Beam order - max EUD
Fx time (min) - max EUD
Min EUD (Gy)
Beam order - min EUD
Fx time (min) - min EUD
%Diff (max,min)

71.4
1234567
8.0
67.0
5261734
14.8
6.4

73.7
1234567
8.0
69.6
5261734
14.8
5.7

73.3
7654321
8.0
68.9
3617254
14.8
6.2

70.5
1234567
8.0
66.6
4527163
14.8
5.7

73.3
7654321
8.0
68.8
5361724
14.8
6.4

Table 6-6 IMRT optimal beam order - results 6 Gy per fraction.
Patient
Max EUD (Gy)
Beam order - max EUD
Fx time (min) - max EUD
Min EUD (Gy)
Beam order - min EUD
Fx time (min) - min EUD
%Diff (max,min)

1

2

3

4

5

73.4
1234567
10.7
68.1
5427163
17.1
7.5

74.9
1234576
11.1
70.2
5261734
17.5
6.4

73.6
7654321
10.7
68.5
3462175
14.7
7.2

70.8
1234567
10.7
66.6
4527163
17.5
6.2

73.6
1234567
10.7
68.3
5361724
17.5
7.4

Table 6-7 IMRT optimal beam order - results 8 Gy per fraction.
Patient
Max EUD (Gy)
Beam order - max EUD
Fx time (min) - max EUD
Min EUD (Gy)
Beam order - min EUD
Fx time (min) - min EUD
%Diff (max,min)

1

2

3

4

5

66.4
1234567
13.41
61.1
5427163
19.81
8.2

67.7
6754213
14.6
63.2
5263714
20.2
6.9

66.6
7654321
13.4
61.6
3461725
19.8
7.8

64.0
1234567
13.4
59.9
4527163
20.2
6.6

66.6
7654321
13.4
61.4
5361724
20.2
8.1

Figure 6-1 Order of beam delivery resulting in the maximum EUD to the PTV (red outline)
for patient 2 at 8 Gy/fraction. The fraction time to deliver this beam order was 14.6 minutes.
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Figure 6-2 Histograms of the EUD values calculated for each of the 720 possible beam order
combinations for the six-field 3DCRT treatments (bin width = 50).

Figure 6-3 Histograms of the EUD values calculated for each of the 5040 possible beam order
combinations for the seven-field IMRT treatments (bin width = 50).
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Figure 6-4 Scatter plot of the overall treatment time versus resulting EUD for 3DCRT
patient 1.

Figure 6-5 Scatter plot of the overall treatment time versus resulting EUD for IMRT patient
1, at 2 Gy per fraction.
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Figure 6-6 Scatter plot of the overall treatment time versus resulting EUD for IMRT patient
2, at 8 Gy per fraction. The maximum EUD is for a treatment time of 14.6 minutes.

6.4

Discussion

The results when treatment time is kept constant indicate the optimal beam order
for the 3DCRT plans is generally for the beam order 1 2 3 4 5 6 or 6 5 4 3 2 1 –
that is starting with a posterior beam and rotating around the patient in a
continuous arc. One thing to note is the weightings of beams used in conformal
prostate EBRT generally have the anterior fields weighted the highest compared
to the lateral beams which travel through the femur heads and the posterior beams
which are weighted the least to avoid the rectum. In delivering the beams in the
order 1 2 3 4 5 6 or 6 5 4 3 2 1 where the posterior fields are delivered first and
last – and the higher weighted fields delivered in the middle of treatment, the
temporal pattern of dose deposition may be unintentionally optimised as described
by Altman et al. (2006) for a single voxel, that is, a pyramid pattern of dose is
delivered to the PTV as a whole. The optimal beam order combination for IMRT
plans appears to be patient and plan specific. Each IMRT plan tested with a
constant treatment time had a unique optimal beam order combination.
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When the treatment time is modified depending on the beam combination, the
optimal beam order delivery for conformal and IMRT prostate treatments is in
agreement with clinical practice; the beam order that provides the most time
efficient treatment fraction also provides the maximum EUD to the target. This is
because the repair of sublethal damage is minimised for shorter treatment
fractions. The average percentage difference between the maximum and minimum
EUD was larger for the IMRT plans (4.4%) compared to the conformal plans
(3.6%). This is due to the longer fraction times and inhomogeneous beams
associated with IMRT. The average percentage difference was seen to increase
with increasing dose per fraction suggesting the influence of temporal effects will
be more significant for hypofractionated treatments.
At smaller doses per fraction (2–4 Gy) the minimisation of intra-fraction sublethal
damage repair appears to outweigh any possible benefits of temporal optimisation
due to beam order alteration. The exception to the findings was IMRT plan 2
when the dose is increased to 6 and 8 Gy per fraction, where the optimal beam
order was 1 2 3 4 5 7 6. The percentage difference in EUD between this beam
order and the beam order of 1 2 3 4 5 6 7 was 0.02%. Therefore it can be
concluded that delivering the beam order which delivers treatment in the fastest
time, will also give the greatest biological effect to the tumour when temporal
effects are considered.
The results of this section may be limited by the approximations used in the model
(constant beam dose rate) and by the lack of more reliable mode parameters (α, β
and T1/2) as discussed previously in chapter 5 (section 5.4).
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CONCLUSIONS AND FUTURE WORK

Using a LQ-based radiobiological model the influence of intra-fraction temporal
dose effects over the whole target area of 3DCRT and IMRT prostate external beam
treatments has been predicted.
It was demonstrated that temporal dose effects are influenced significantly by the
radiobiological parameters associated with various tissues (α, β, and T1/2) as well as
treatment time and dose per fraction. Temporal dose effects are particularly sensitive
to the β value and T1/2 when the treatment time is comparable to this repair time.
When temporal dose effects are considered, cell kill over the target volume,
particularly in IMRT plans, was found to be non-uniform, despite modern planning
systems optimising for a uniform physical dose. Furthermore, incorporation of
temporal dose effects was found to reduce the overall treatment effectiveness by on
average 1.3% for 3DCRT and 3% for IMRT plans. It was demonstrated that it is
possible to visualise these effects at the treatment planning stage to offer extra
information when making clinical decisions on the quality of various plans.
For the theoretical scenario of optimising the temporal dose pattern to every voxel in
the target volume the impact on treatment effectiveness was found to be modest – on
average a 0.8% increase in EUD for a 2 Gy per fraction IMRT treatment plan. More
promising results were observed for larger dose per fraction treatments. It is therefore
recommended that temporal dose effects should be considered in the treatment
planning of modulated treatments, especially in cases where the tumour exhibits a
large β component (low α/β), short repair half-time and where the treatment is
protracted and/or hypofractionated (e.g. Cyberknife and stereotactic treatments).
The results presented in chapter 6 confirm that instantaneous delivery of dose is still
the optimal dose pattern to maximise cell kill. It can be concluded that dynamic arc
treatments (i.e. VMAT) which are capable of delivering dose within a single or
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double arc and reduce the fraction times compared to IMRT (Sze et al. 2012), are
advantageous for maximising cell kill in prostate treatments.
This thesis focused on maximising cell kill in the target volume. However, this
comes at the expense of surrounding normal tissues where it would be advantageous
to deliver the V-shape pattern of dose. This scenario – minimising cell kill to normal
tissues due to the pattern of dose delivery was beyond the scope of this thesis, and
remains as future work to be investigated.
Other future work includes extending the model to investigate other treatment
modalities for example, stereotactic treatments and Cyberknife where large doses per
fraction are delivered and the treatment fraction times can be of the order of 30
minutes. Improving the accuracy of the model is something that could also be
investigated in future. By exporting the dose cubes for each beam segment, more
accurate predictions of G can be achieved. This was restricted in this work due to the
limitations of the planning systems used.
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